March 2025, Southern Research Awards Therapeutics Development Fund Grant to Kalm Therapeutics
October 2024, NIH Awards $1.6M Grant Towards Kalm Patch Development
SEPTEMBER 2024, Kalm adds former GSK Director, Dr. Tomoko Maeda-Chubachi, to the team as Chief Medical Officer
AUGUST 2024, Kalm adds veteran drug developer, Dr. Tacey Viegas, to the team as Chief Development Officer.
AUGUST 2024, Kalm announces oversubscribed seed round.
JULY 2024, Kalm CEO, Chris Seibert, interviewed at BIO International 2024 (San Diego).
Copyright © 2025 Kalm - All Rights Reserved.
Powered by
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.